Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.
glucagon‐like peptide‐1 receptor agonist
glycaemic control
tirzepatide
type 2 diabetes
weight change
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
24 May 2024
24 May 2024
Historique:
revised:
01
05
2024
received:
21
03
2024
accepted:
09
05
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
24
5
2024
Statut:
aheadofprint
Résumé
Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) dual receptor agonist (RA) that reduces glycated haemoglobin (HbA1c) and weight in patients with type 2 diabetes. We assessed the effectiveness of tirzepatide in real-world use in an Arab population. Review of clinical data from a specialist outpatient diabetes centre; study time points and outcome measures were pre-specified. Tirzepatide was initiated in 8945 patients between 24 October 2022 and 31 December 2023. Of these, 3686 individuals reached 40 weeks of follow-up. At initiation, the mean ± SD age was 54.1 ± 11.5 years, body mass index 34.6 ± 6.0 kg/m In real-world use, tirzepatide significantly reduced HbA1c levels and weight and was well tolerated. Previous GLP-RA use was associated with significantly lesser HbA1c and weight reduction, and previous metabolic bariatric surgery was associated with greater weight loss.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP‐1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS‐1): a double‐blind, randomised, phase 3 trial. The Lancet. 2021;398:143‐155.
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503‐515.
Ludvik B, Giorgino F, Jódar E, et al. Once‐weekly tirzepatide versus once‐daily insulin degludec as add‐on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS‐3): a randomised, open‐label, parallel‐group, phase 3 trial. The Lancet. 2021;398:583‐598.
Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS‐4): a randomised, open‐label, parallel‐group, multicentre, phase 3 trial. Lancet. 2021;398:1811‐1824.
Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs.placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS‐5 randomized clinical trial. JAMA. 2022;327:534‐545.
Davies MJ, Aroda VR, Collins BS, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;2022(45):2753‐2786.
Administration USFAD. Use of real‐world evidence to support regulatory decision‐making for medical devices ‐ guidance for industry and food and drug administration staff. Guidance for Industry and Food and Drug 2017.
Carls GS, Tuttle E, Tan RD, et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real‐world use of GLP‐1 RA and DPP‐4 therapies in patients with type 2 Diabetes. Diabetes Care. 2017;40:1469‐1478.
Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon‐like Peptide‐1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38:390‐402.
Williams DM, Ruslan AM, Khan R, et al. Real‐world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study. Diabetes Ther. 2021;12:801‐811.
Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP‐1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo‐controlled and active comparator‐controlled phase 2 trial. Lancet. 2018;392:2180‐2193.
Overgaard RV, Lindberg SØ, Thielke D. Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: a model‐based approach. Diabetes Obes Metab. 2019;21:43‐51.
Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH. Outcomes in GLP‐1 RA‐experienced patients switching to once‐weekly semaglutide in a real‐world setting: the retrospective, observational EXPERT study. Diabetes Ther. 2021;12:879‐896.
Jain AB, Kanters S, Khurana R, Kissock J, Severin N, Stafford SG. Real‐world effectiveness analysis of switching from Liraglutide or Dulaglutide to Semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE‐DM study. Diabetes Ther. 2021;12:527‐536.
Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon‐like peptide 1‐induced deceleration of gastric emptying in humans. Diabetes. 2011;60:1561‐1565.
Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi‐center study. Surg Obes Relat Dis. 2017;13:491‐500.
King WC, Hinerman AS, Belle SH, Wahed AS, Courcoulas AP. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. JAMA. 2018;320:1560‐1569.
ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes‐2023. Diabetes Care. 2023;46:S158‐S190.
Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre‐specified meta‐analysis. Nat Med. 2022;28:591‐598.
Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics. Am Heart J. 2024;267:1‐11.
Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS‐3 MRI): a substudy of the randomised, open‐label, parallel‐group, phase 3 SURPASS‐3 trial. Lancet Diabetes Endocrinol. 2022;10:393‐406.
Company ELA. A study of tirzepatide (LY3298176) in participants with nonalcoholic steatohepatitis (NASH) (SYNERGY‐NASH). Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04166773
Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP‐1 receptor agonist tirzepatide: a systematic review and meta‐analysis. Diabetologia. 2022;65:1251‐1261.
Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP‐1 receptor co‐agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21:169.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP‐1 receptor agonists in the treatment of type 2 diabetes ‐ state‐of‐the‐art. Mol Metab. 2021;46:101102.
Brown RE, Bech PG, Aronson R. Semaglutide once weekly in people with type 2 diabetes: real‐world analysis of the Canadian LMC diabetes registry (SPARE study). Diabetes Obes Metab. 2020;22:2013‐2020.